Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 25-34 , January 2009

Independent role of blood pressure on cardiovascular risk factors in nondiabetic, obese African-American women with family history of type 2 diabetes: Implications for metabolic syndrome components

  • Trudy Gaillard, RN, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author: Trudy Gaillard, RN, PhD, 495 McCampbell Hall, 1581 Dodd Drive, Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University, Columbus, Ohio 43210. Tel: 614-688-4184; fax: 614-292-1550
    • ,
  • Dara Schuster, MD
    • ,
  • Kwame Osei, MD

Received 11 June 2008 ,Accepted 29 July 2008.

References 

  1. Field L, Burt V, Cutler J, Hughes J, Roccella E, Sorlie P. The burden of adult hypertension in the United States 1999–2000: a rising tide. Hypertension. 2004;44:398–404
  2. Wong N, Lopez V, L'Italien G, Chen R, Kiline S, Franklin S. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med. 2007;167:2431–2436
  3. Cooper R, Rotimi C, Ataman S, McGee D, Osotmehin B, Kadiri S, et al. Prevalence of hypertension in seven populations of African origin. Am J Public Health. 1997;87:160–169
  4. Liu K, Ruth K, Flack J, Jones-Webb R, Burke G, Savage P, et al. Blood pressure in young black and whites: relevance of obesity and lifestyle factors in determining difference. Circulation. 1996;93:60–66
  5. Dyer A, Liu K, Walsh M, Kiefe C, Jacobs D, Bild D. Ten-year incidence of elevated blood pressure and its predictors: the CARDIA Study (Coronary Artery Risk Development in (Young) Adults). J Hum Hypertens. 1999;13:13–21
  6. Manolio T, Savage P, Burge G, Liu K, Wagenknecht L, Sidney S, et al. Association of fasting insulin with blood pressure and lipids in young adults (The CARDIA Study). Arteriosclerosis. 1990;10:430–436
  7. Gillum R, Mussolino M, Madans J. Diabetes mellitus, coronary heart disease incidence, and death from all cause in African American and European American women (The NHANES I Epidemiologic Follow-up Study). J Clin Epidemiol. 2000;53:511–518
  8. Grundy S. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004;89:2595–2600
  9. Feldman H, Klag M, Chiapella A, Whelton P. End-stage renal disease in US minority groups. Am J Kidney Dis. 1992;19:397–410
  10. Jones C. Hypertension and renal dysfunction: NHANES III. J Am Soc Neph. 2003;14:S71–S75
  11. Duru O, Li S, Jurkovitz C, Bakris G, Brown W, Chen S, et al. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008;51:192–198
  12. Saad M, Lillioja S, Nyomba B, Castillo C, Ferraro R, DeGregorio M, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324:733–739
  13. Srinivasan S, Myers L, Berenson G. Risk variables of insulin resistance syndrome in African-American and Caucasian young adults with microalbuminuria: the Bogalusa Heart Study. Am J Hypertens. 2000;13:1274–1279
  14. Falkner B, Sherif K, Sumner AE, Kushner H. Blood pressure increase with impaired glucose tolerance in young adult American blacks. Hypertension. 1999;34:1086–1090
  15. Hutchinson R, Watson R, Davis C, Barnes R, Brown S, Romm F, et al. Racial differences in risk factors for atherosclerosis (The ARIC Study: Atherosclerosis Risk in Communities). Angiology. 1997;48:279–290
  16. Haffner S, D'Agostino R, Saad M, Rewers M, Mykkanen L, Shelby J, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites (The Insulin Resistance Atherosclerosis Study). Diabetes. 1996;45:742–748
  17. Palaniappan L, Carnethon M, Wang Y, Hanley A, Fortmann S, Haffner S, et al. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27:788–793
  18. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  19. Ford E, Giles W, Mokdad A. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care. 2004;27:2444–2449
  20. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. JAMA. 2002;287:356–359
  21. Osei K, Schuster DP. Effects of race and ethnicity and ethnicity on insulin sensitivity, blood pressure, and heart rate in 3 ethnic populations; comparative studies in African-Americans, African immigrants (Ghanaians), and white Americans using ambulatory blood pressure monitoring. Am J Hypertens. 1996;9:1157–1164
  22. Osei K, Gaillard T, Schuster DP. Cardiovascular risk factors in African Americans with varying degrees of glucose intolerance. Diabetes Care. 1999;22:1588–1590
  23. Meis S, Schuster D, Gaillard T, Osei K. Metabolic syndrome in non-diabetic, obese first degree relatives of African American patients with type 2 diabetes (African-American triglycerides, HDL, and insulin resistance paradox). Ethn Dis. 2006;16:830–836
  24. Gaillard T, Osei K, Schuster D, Green P, Bossetti B. Gender differences in insulin sensitivity and glucose dependent glucose disposal in nondiabetic, high risk African-American women and men. Ethn Dis. 1997;16:830–856
  25. Howard B, Criqui M, Curb D, Rodabough R, Safford M, Santoro N, et al. Risk factor clustering in the insulin resistance syndrome and relationship to cardiovascular disease in postmenopausal white, black and Hispanic and Asian/Pacific Islander women. Metabolism. 2003;53:362–371
  26. Sumner A, Finley K, Genovese D, Criqui M, Boston R. Fasting triglycerides and the triglyceride-HDL-cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med. 2005;165:1395–1400
  27. Cowie C, Howard B, Harris M. Serum lipoproteins in African Americans and whites with non-insulin-dependent diabetes in the US population. Circulation. 1991;90:1185–1193
  28. Haffner S, D'Agistino R, Goff D, Howard B, Festa A, Saad M, et al. LDL size in African Americans, Hispanics and Non-Hispanic whites: The Insulin Resistance Atherosclerosis Study. Arteriol Thromb Vasc Biol. 1999;39:2234–2240
  29. World Health Organization Study Group. Diabetes mellitus (World Health Organization, Geneva, Switzerland). Technical Report Series. 1985;727:88
  30. Mathews D, Hosker J, Rudenski A, Taylor B, Treacher D, Turner R. Homeostasis model assessment of insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  31. Boffins J, Vaccarino V, Zhang H, Kasl S. Excess type 2 diabetes in African-American women and men aged 40-74 and socioeconomic status: evidence for the Third National Health and Nutrition Examination Survey. J Epidemiol Comm Health. 2000;54:839–845
  32. Ong K, Cheung B, Man Y, Lau C, Lam K. Prevalence, awareness, treatment and control of hypertension among United States Adults, 1988–2004. Hypertension. 2007;49:69–75
  33. Lovejoy J, Bretonne J, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism. 1996;45:1119–1124
  34. Albu J, Murphy L, Frager D, Johnson J, Pi-Sunyer F. Visceral fat and race dependant health risks in obese nondiabetic premenopausal women. Diabetes. 1997;46:456–462
  35. Taylor H, Liu J, Wilson G, Golden S, Crook E, Brunson C, et al. Distinct component profiles and high risk among African-American with the metabolic syndrome: the Jackson Heart Study. Diabetes Care. 2008;31:1248–1252
  36. Crowther N, Ferris W, Ojwang P, Rheeder P. The effect of abdominal obesity on insulin sensitivity and serum lipid and cytokine concentrations in African women. Clin Endocrinol. 2006;64:535–541
  37. Schutte AE, van Burren D, van Rooyen JM, Huisman HW, Schutte R, Malan L, et al. Inflammation, obesity and cardiovascular function in Africans and Caucasians from South Africa: the POWIRS Study. J. Human Hypertens. 2006;20:850–859

 Dr. Schuster participates with the Speakers Bureau for Novo Nordisk and GlaskoSmithKline Pharmaceuticals. Dr. Osei participates with the Speakers Bureau for Novo Nordisk and Takeda Pharmaceuticals. Grants from Merck and Eli Lilly/Amilyn Pharmaceuticals.

PII: S1933-1711(08)00147-2

doi: 10.1016/j.jash.2008.07.003

Journal of the American Society of Hypertension
Volume 3, Issue 1 , Pages 25-34 , January 2009

Article Tools